Ph.D. Ioannis P Trougakos - Research Lecturer - National Hellenic Research Foundation | LinkedIn
Olive Bioactives: applications and prospects | LE STUDIUM
Home
Ioannis Trougakos
Natural compounds with anti-ageing activity - Natural Product Reports (RSC Publishing) DOI:10.1039/C3NP70031C
Ph.D. Ioannis P Trougakos - Research Lecturer - National Hellenic Research Foundation | LinkedIn
Ioannis P. Trougakos's research works | National and Kapodistrian University of Athens, Athens (uoa) and other places
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment | Blood Cancer Journal
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment - Abstract - Europe PMC
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine - Terpos - 2021 - American Journal of Hematology - Wiley Online Library
PARTNERS — Emotive - Storytelling for cultural heritage
Amazon.com: Molecular Mechanisms and Models of Aging, Volume 1119 (Annals of the New York Academy of Sciences): 9781573316866: Gonos, Efstathios S., Trougakos, Ioannis P., Chondrogianni, Niki: Books
Frontiers | Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection | Immunology
Ioannis P. Trougakos's research works | National and Kapodistrian University of Athens, Athens (uoa) and other places
Identification of new biomarkers and therapeutic targets for MDR tumours - Stratagem
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications | Journal of Biomedical Science | Full Text
Biomedicine Archives - Page 2 of 3 - Neuro-Psychology
Comparison of neutralizing antibody responses against SARS‐CoV‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? - Terpos - 2021 -
Ioannis Trougakos * - AD Scientific Index 2022
PDF) Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
Genentech: Baris Bingol | Principal Scientist, Neuroscience
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment | Blood Cancer Journal
Prof. Ioannis P. TROUGAKOS – Mu.Ta.Lig – COST ACTION CA15135
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine | SpringerLink
